Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium

Title: The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium
Authors: Obermayr, Eva; Reiner, Angelika; Brandt, Burkhard; Braicu, Elena Ioana; Reinthaller, Alexander; Loverix, Liselore; Concin, Nicole; Woelber, Linn; Mahner, Sven; Sehouli, Jalid; Vergote, Ignace; Zeillinger, Robert
Source: ISSN:2072-6694 ; Cancers, vol. 13 (11), Art.No. ARTN 2613.
Publisher Information: Multidisciplinary Digital Publishing Institute (MDPI)
Publication Year: 2021
Subject Terms: Science & Technology; Life Sciences & Biomedicine; Oncology; primary epithelial ovarian cancer; circulating tumor cells; long-term survival; MOLECULAR CHARACTERIZATION; BREAST-CANCER; EXPRESSION; METASTASIS; SURVIVORS; MARKERS; MODELS; 1112 Oncology and Carcinogenesis; 3211 Oncology and carcinogenesis
Description: INTRODUCTION: We previously reported the prognostic impact of circulating tumor cells (CTCs) in a multicenter study on minimal residual disease in primary ovarian cancer. With additional follow-up data, we evaluated the combined CTC approach (CTCscombo), in particular for the patients who had survived more than five years. MATERIAL AND METHODS: Blood samples taken at baseline and six months after adjuvant treatment (follow-up) were assessed by quantitative PCR (qPCR) measuring PPIC transcripts and immunofluorescent staining (IF). A positive result with either IF or qPCR was classified as CTCcombo-positive. Further, PPIC was assessed in the primary tumor tissue. RESULTS: The concordance of IF and qPCR was 65% at baseline and 83% after treatment. Results showed that 50.5% of the baseline and 29.5% of the follow-up samples were CTCcombo-positive. CTCscombo after treatment were associated with increased mortality after adjusting for FIGO stage (HR 2.574, 95% CI: 1.227-5.398, p = 0.012), a higher risk of recurrence after adjusting for peritoneal carcinosis (HR 4.068, 95% CI: 1.948-8.498, p < 0.001), and increased mortality after five survived years. DISCUSSION: The two-sided analytical approach revealed CTC subpopulations associated with ovarian cancer progression and may illuminate a potential treatment-related shift in molecular phenotypes. That approach can identify patients who have elevated risk of recurrence and death due to ovarian cancer and who may require risk-adapted treatment strategies. ; sponsorship: This research was funded by the Sixth Framework Programme FP6-LIFESCIHEALTH (Project "OVCAD-Diagnosis of a Silent Killer", project no LSHC-CT-2005-018698). (Sixth Framework Programme FP6-LIFESCIHEALTH (Project "OVCAD-Diagnosis of a Silent Killer")|LSHC-CT-2005-018698) ; status: Published
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: https://lirias.kuleuven.be/handle/123456789/680897; https://doi.org/10.3390/cancers13112613; https://pubmed.ncbi.nlm.nih.gov/34073412
DOI: 10.3390/cancers13112613
Availability: https://lirias.kuleuven.be/handle/123456789/680897; https://lirias.kuleuven.be/retrieve/1d8b6efa-a9bf-4b56-9c8c-64b615f30d16; https://doi.org/10.3390/cancers13112613; https://pubmed.ncbi.nlm.nih.gov/34073412
Rights: info:eu-repo/semantics/openAccess ; public ; All rights reserved
Accession Number: edsbas.142E90FF
Database: BASE